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about IL-23 efficacy in the axial domain. Imaging can be 
used for patient inclusion and as an outcome measure in 
prospective trials. A recent study specifically addressing 
the efficacy of secukinumab, an IL-17A inhibitor, in 
axial psoriatic arthritis included MRI scans and clinical 
outcome measures to provide objective evidence of 
efficacy.10 Although relying on MRI imaging can also 
have limitations, this approach is currently the only way 
to provide objective evidence of spinal efficacy.
Studies addressing the efficacy of different therapies 
in axial psoriatic arthritis are of high importance for 
treatment guidelines and for daily clinical practice. 
Current treatment guidelines in psoriatic arthritis 
rely largely on the results of studies in primary axial 
spondyloarthritis. Evidence of efficacy in axial psoriatic 
arthritis would certainly affect not only the guidelines 
but also the choice of appropriate treatment options in 
individual patients. 
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Adult-onset Still’s disease following COVID-19 vaccination
The spread of the COVID-19 pandemic has led to 
unprecedented acceleration of vaccine development. 
Although tested on thousands of people before 
regulatory approval, very rare adverse events can manifest 
during roll-out of vaccines to the general population.
During follow-up of the COVID-19 vaccine roll-out, 
side-effects related to a hypothetical immune system 
overstimulation or over-reaction have been described, 
such as adenoviral vector vaccine-induced immune 
thrombotic thrombocytopenia1 and systemic immune-
mediated diseases after mRNA-vaccine.2,3 However, to 
our knowledge, there have been no reports of Adult-
onset Still’s disease (AOSD) after vaccination with a 
COVID-19 adenoviral vector vaccine (ie, ChAdOx1 
nCoV-19 vaccine).
AOSD is considered a rare inflammatory disorder 
affecting young adults and IL-1 has a central role in 
the pathogenesis. Inhibition of IL-1β by monoclonal 
antibodies and of the IL-1 receptor by antagonists, 
substantially ameliorates clinical symptoms.4 Increasing 
evidence points towards a similar role for IL-1 in COVID-19 
hyperinflammation, and several reports suggest 
that inhibition of IL-1 substantially reduces hyper-
inflammation, respiratory insufficiency, and mortality in 
patients in hospital with severe COVID-19.5
Here, we report the case of a 36-year-old male, 
without any comorbidities or family history of 
autoimmune diseases, who developed AOSD after the 
first dose of the ChAdOx1 nCoV-19 vaccine. The day 
after the vaccination, he developed high-grade fever 
(>39°C) that lasted for 48 h. The fever then returned 
4 days later, preceded by sore throat and accompanied 
by evanescent and not pruritic rash and chest pain. He 
was treated at home with antibiotics and non-steroidal 
anti-inflammatory drugs without improvement. He 
presented to the emergency room of a local hospital 
(Santo Spirito Hospital, Rome, Italy) due to the 
increasing severity of his symptoms and was admitted 
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to the internal medicine unit for further exploration. 
On admission, the patient was febrile with tachycardia, 
with chest pain exacerbated by inspiration. His pulse 
was 120 beats per min, temperature was 38·9°C, blood 
pressure was 120/60 mm Hg, and oxygen saturation 
was 96%. Nothing relevant was found on physical 
examination.
After being tested for viral and bacterial agents, which 
were all negative, given the presence of leukocytosis 
(30·83 × 109 cells per L with 86·6% neutrophil) and 
fever, broad-spectrum antibiotic treatment was started, 
without any clinical or laboratory response during 
10 days. The treating physicians suspected that the 
patient might have an autoimmune condition and so 
started him on methylprednisolone 0·75 mg/kg, and 
the fever disappeared after 3 days of treatment. To 
further investigate the case, the patient was transferred 
to our rheumatology unit at the Fondazione Policlinico 
Universitario Agostino Gemelli IRCCS (Rome, Italy).
21 days after the first episode of fever, physical 
examination and vital parameters were normal, with 
chest pain exacerbated by inspiration being an isolated 
finding. Despite the increase of corticosteroid treatment 
at 1mg/kg, laboratory tests confirmed persistent 
leukocytosis, abnormal liver function, high acute-phase 
reactants (C-reactive protein 188 mg/L, erythrocyte 
sedimentation rate 85 mm/h, IL-6 11·8 ng/L, soluble 
IL-2R 9·74 UI/L), high serum ferritin (1482 ng/mL, 
normal range 12–240 ng/mL), and transitory increased 
troponin (1695 pg/dL).
RT-PCR SARS-CoV-2 tests were done several times 
with negative results. Microbiological routine tests 
(including common viral serology and bacterial blood 
cultures) were negative for anything clinically relevant. 
An autoimmune panel was normal, except for the 
presence of beta-2-glicoprotein IgG (29·7 U/mL) and 
lupus anticoagulant.
Ecocardiography showed pericardial effusion, 
without modification of ejection fraction. Lung and 
abdominal ultrasound assessments and CT scan revealed 
bilateral pleural effusion, posterior wall pericardial 
effusion, subcentimetric lymphadenopathy, and mild 
splenomegaly. A PET-CT scan was done and excluded 
neoplasms or vasculitis, but confirmed cardiophrenic 
lymphadenopathies and pleuropericardial effusion. 
cardiac MRI was compatible with recent myopericarditis 
(figure).
In accordance with Yamaguchi criteria,4 a diagnosis 
of AOSD was made and corticosteroid treatment 
was continued. Because of myocardial involvement, 
persistent leukocytosis and high ferritin (946 ng/mL), 
treatment with the IL-1 receptor antagonist anakinra 
was started (100 mg daily). After 4 days, we observed a 
complete normalisation of symptoms and blood tests 
and the patient was discharged.
At 1 month of follow-up, he reported feeling well and 
ferritin levels and inflammatory markers were within 
normal limits.
Figure: PET (A, B), PET-CT (C, D), and cardiac MRI (E–G) scans of a patient 
with recent myopericarditis
The figure shows the involvement of pericardium with three different imaging 
techniques: PET, PET-CT, and MRI, 14 and 21 days after initial symptoms onset. 
Images A (coronal PET) and C (fused PET-CT images) show increased 
radiopharmaceutical uptake in the pericardium, and images B (axial PET) and 
D (PET-CT slices) in lymph node located in left cardiophrenic angle. MRI delayed-
enhancement images acquired on the mid-ventricular short-axis (E) and 
horizontal long axis (F) planes show very high signal in the pericardium 
correspondence, almost circumferentially affected. A suspected thin underlying 
epicardial and myocardial involvement can be seen. On T2-weighted imaging with 
fat suppression on the same plane as in image E (F) presence of hypo intense 
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The first case of AOSD after COVID-19 has recently 
been reported.6 Systemic inflammation, unremitting 
fever, high serum ferritin, and a hyperinflammatory 
syndrome that induces major organ involvement 
characterise both AOSD7 and severe COVID-19,8 
suggesting they might be triggered by the same 
mechanisms.
In the present case, the strong temporal association 
between the symptoms and COVID-19 vaccination 
prompted us to suspect a causal connection, since similar 
AOSD cases have been observed after vaccinations 
for influenza, hepatitis A, and hepatitis B.9 However, 
we cannot exclude the possibility that the timing 
with regards to vaccination was coincidental. Possible 
pathogenic mechanisms might include high levels of 
spike protein production after vaccination, that also 
cause the immune system activation in COVID-19, 
suggesting that the inflammatory storm of AOSD can be 
triggered either by the infection or by the vaccination. 
Intrinsic adjuvant activity of adenoviral particles 
targeting innate immune cells and ultimately resulting 
in the production of type I interferon and multiple pro-
inflammatory cytokines, might be another potential 
cause. 10 Finally, the role of vaccines-adjuvants such as 
polysorbate 80, which is present also in the influenza 
and hepatitis vaccines, might also be  considered.3 
The response of COVID-19 to IL-1 blockade, known to 
produce substantial benefit in AOSD, further supports the 
hypothesis of a strict pathogenic connection between 
hyperinflammatory syndromes and severe COVID-19.5
Adult-onset Still’s disease after mRNA COVID-19 vaccine
We report a case of severe adult-onset Still’s disease 
(AOSD) presenting in a patient after receiving 
the mRNA-1273 COVID-19 vaccine (Moderna). A 
45-year-old healthy woman developed a sore throat, 
intermittent headache, and fever of 38·3°C at 5 days 
after the second dose of the vaccine, approximately 
one month after the first dose. Over the next few 
days, she continued to have persistent daily fevers of 
up to 40°C despite consistent use of acetaminophen 
and nonsteroidal anti-inflammatory drugs. She 
subsequently developed severely debilitating myalgias, 
arthralgias, and pleurisy that ultimately prompted her to 
seek medical attention.
On admission to hospital, she had daily fevers 
of ≥39˚C and developed acute hypoxic respiratory 
failure requiring a 100% non-rebreather mask. Initial 
laboratory testing was notable for a leukocytosis, 
elevated erythrocyte sedimentation rate (85 mm/h; 
reference range 0–20 mm/h), C-reactive protein, and 
ferritin concentration (table). Cardiac biomarkers were 
increased, including troponin I to 0·35 ng/mL (reference 
range 0·00–0·04 ng/mL) and NT-proBNP to 1815 pg/mL 
(reference range 0–125 pg/mL). Imaging studies were 
notable for diffuse bilateral infiltrates on chest x-ray, 
no pulmonary embolus on chest CT scan, and left 
supraclavicular lymphadenopathy on neck CT and MRI. 
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